• The submitting author is responsible for the following:
  o    The submitter serves as point of contact for all correspondence regarding the abstract.
  o    Ensuring that all authors have read the abstract and agreed to be co-authors. Failure to get approval from all authors will result in rejection of the abstract.
  o    Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by ACMG.
  o    Ensuring that all authors approve of submitting this work for presentation and publication.
  o    Abiding by all formatting
• The author(s) agree(s) to materially confine the presentation to information in the abstract, if accepted for presentation. If an author has more than one abstract accepted, each presentation will be materially confined to the information in the abstract selected for the specific session.
• The presenting author will be available to present the abstract if selected for the program. The author(s) will immediately notify ACMG if the first author is not the presenting author.
• The presenting author must be one of the co-authors listed on the submitted abstract. The presenting author must be confirmed prior to abstract submission.
• An individual may be first author (i.e., presenting author) of more than one abstract. If the first author should have multiple accepted Posters and has a conflict with the Poster presentation schedule, then it is acceptable to designate one of the co- authors to present one of the Posters.

Completion of all required information in the online abstract submission system serves as an agreement. It certifies the ACMG abstract submitter's understanding of the rules for participation contained in the online abstract submission program.

• Each abstract author agrees and certifies that he or she:
  o    has read all of the rules and agrees to be bound by them,
  o    is responsible for submission of the abstract in accordance with the rules, and
  o    waives any and all claims against ACMG and any reviewer arising out of or relating to the abstract submission and review process, including, but not limited to peer review and the grading of abstracts.

• The abstract must address scientific questions, detail clinical observations, and/or contain primary scientific data. We encourage authors to highlight why their abstract is novel or how it provides a unique contribution or perspective.
• Authors assign copyright of the abstract to ACMG upon submission, unless one of the authors is a U.S. Federal employee (in such case, ACMG does not hold copyright). This means that the identical abstract may not be republished or submitted to another meeting.
• All research and studies reported in submitted abstracts that involve human and animal subjects must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.
• Interim analysis of a prospective randomized clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid. If your abstract involves interim analysis, use the Interim Analysis of a Clinical Trial section of the abstract form to explain the details of your study. The reviewers will have this information available during their evaluation.
• No revisions can be made after the abstract submission deadline (November 18, 2022).
• The presentation at the Annual Meeting must reflect the submitted abstract. In particular, the abstract title, authorship, and scientific content of the presentation at the Annual Meeting must reflect the submitted abstract.
• Abstracts should be written in clear and concise English, so that reviewers can focus solely on the scientific merits of the submission. We encourage non-English-speaking authors to have their abstracts checked for grammar and spelling prior to submission.
• An abstract can be submitted if:
  • It is unpublished and original
  • It is accepted for publication but not yet published
  • Encore presentations are allowed, but only if the material was previously presented at non-genetics meeting within the last 6 – 12 months.

• After the submission deadline, all completed and eligible abstracts will be made available to the ACMG Abstract Reviewers for review and scoring.
• Abstracts will be evaluated and scored solely on their scientific merits.
• Incomplete abstracts will not be reviewed.
• Abstracts based on the same study with the same content reworded must not be submitted as multiple abstracts. Abstracts that are simply different versions of a single study will be rejected.
• Abstracts will be peer reviewed according to the subject categories. Authors must indicate during online submission the appropriate review category (one only). All category selections will be final. There will be NO re-classification of abstracts after the abstract submission site has been closed. Abstracts submitted to an inappropriate category are scored in that category and may receive a lower score as a result.
• All abstracts submitted will be considered eligible for one presentation format as explained above: either a platform or a poster.
  o   Platform Presentations are formal oral presentations (15 minutes total) that include a brief discussion. Of the abstracts selected, four of the highest-rated will be featured in a special plenary session. It is important to note that the entire educational program will be delivered in person. Pre-recorded presentations or remote presentations are NOT allowed. Additionally, platform presenters will need to follow standard presentation protocols with completion of HIPAA documentation, financial disclosure, and provision of learning objective and if an accredited session, a peer-reviewed test question per guidelines.
  o   Poster Sessions include the display of traditional printed posters as well as electronic posters for online viewing. All poster presenters are required to have both. Instructions for the ePosters will be provided in January 2023.

Acceptance/Rejection Notification

• Notification regarding acceptance or rejection of abstracts will be sent to the submitting author the week of December 19, 2022, by email; consequently, an accurate email address is critical. If your abstract is accepted, the email will specify whether it is accepted as a Platform or Poster presentation.
• Once the abstracts are accepted, they will be formatted for publication in an online supplement to Genetics in Medicine Open. Therefore, abstract authors should carefully review their abstracts before submission to ensure that all authors and their affiliations are listed correctly.
• The decision of the ACMG Program Committee regarding the acceptance and presentation of abstracts is final.

• Once an abstract is accepted, a written request to withdraw must be submitted no later than February 10, 2023, to Education@ACMG.net if the first author decides to withdraw the abstract for any reason. Abstract withdrawal requests received after the deadline will be considered on a case-by-case basis.
• ACMG reserves the right to withdraw abstracts that are in violation of the College’s policies and guidelines, or GIM’s formatting guidelines, have been deemed scientifically unsound, or have been found to include inaccurate data, etc.
• For any abstract submitters with non-withdrawn abstracts who do not fulfill their professional commitment of presenting at the meeting, ACMG reserves the right to consider this information in the selection of abstracts for presentation in the future.

All meeting attendees, presenters, authors, the media, exhibitors, institutions, industry and all other organizations and individuals are required to abide by the ACMG Annual Meeting Embargo Policy.

All abstracts, posters and oral (platform) scientific presentations are under strict embargo once ACMG has notified a presenter of their abstract’s acceptance.

An embargo means that information from any abstract, poster or presentation is confidential and may not be announced, publicized, or disseminated before the embargo lift dates and times, as detailed below. The purpose of the ACMG Embargo Policy below is to protect the scientific integrity of all content presented at the ACMG Annual Clinical Genetics meeting and to ensure publicity is not released prematurely.

All ACMG Annual Clinical Genetics Meeting content to be presented or published is embargoed until the time of an actual conference presentation. ACMG has updated its guidelines to reflect the current e-publishing and online environment. The Embargo Policy below provides more details regarding the types of content that are embargoed.

The ACMG Embargo Policy is based on trust. Violation of the ACMG Embargo Policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate may be taken. Media who violate the Embargo Policy may lose their ACMG press credentials and be removed from the list to receive embargoed copies of ACMG news releases.

Specific Embargo Dates and Times:
Abstracts – Embargoed until February 10, 2023; posted on the ACMG Meeting website

Accepted abstracts will be made available online in advance of the ACMG Annual Clinical Genetics Meeting and will also be published in a special online supplement to our official open access journal, Genetics in Medicine Open. The information contained in abstracts is embargoed until the abstracts are available and published online. Information contained in abstracts may not be released in any format, including preprints, until the abstracts appear online.

ACMG continues to require that any information that goes beyond that contained in the submitted abstract is under embargo until the times specified below.

Posters – Embargoed until Wednesday, March 15, 2023, at 5:00 pm MT
For abstracts selected for posters, the embargo will lift when the e-posters are published via ACMG.

Oral (Platform) Scientific Presentations – Presentations embargoed until start of live session

The embargo for all scientific presentations will lift at the start time of the session in which the live presentation is being made. Interviews with presenters as well as any information to be presented for the first time at the ACMG Annual Meeting are embargoed until the time of the live presentation in which the paper will be given.

For questions about the ACMG embargo policy, email education@acmg.net.

Financial Disclosure Policy (to be completed by Platform Presenter)
The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to the improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias. The Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Standard to Prevent Commercial Bias and Marketing in Accredited Continuing Education
ACCME requirements designed to ensure that CME activities are independent and free of commercial bias.

Accredited continuing education must protect learners from commercial bias and marketing.

The accredited provider must ensure that all decisions related to the planning, faculty selection, delivery, and evaluation of accredited education are made without any influence or involvement from the owners and employees of an ineligible company.

Accredited education must be free of marketing or sales of products or services. Faculty must not actively promote or sell products or services that serve their professional or financial interests during accredited education.

The accredited provider must not share the names or contact information of learners with any ineligible company or its agents without the explicit consent of the individual learner.

Platform Presenters' Responsibility Regarding Financial Disclosure (ACCME Compliance)

• The presenting author for a platform presentation will be contacted and must complete the online financial disclosure form and additional items pertaining to their presentation and participation.
• Employees of ACCME defined ineligible company may not present an accredited platform presentation.
• The content of the information with which you are involved will promote quality in health care or advances in science and will not promote a specific proprietary or commercial interest. Content for this publication will be well-balanced and unbiased.

ACMG Education Policies
Please review the policies below regarding the ACMG Education program

• Financial Disclosures and Mitigation Procedure
• ACMG Content Validation Policy
• ACMG Content Branding Policy

The abstract submission site opens on October 4, 2022.

All abstracts must be submitted by Friday, November 18, 2022, 11:59 pm PT. Submissions that are incomplete by the deadline will be rejected.

• Abstracts must be submitted online through the official online abstract submission system. Emails and word processing files not submitted through the site will not be accepted.
• Once you have submitted the title page information, a draft of your abstract will be saved, and you will be able to return to edit and update it at any time until November 18, 2022, at 11:59 pm PT. You can log back into the abstract portal.
• For technical support, please click on the "Feedback and Support" tab on the right-hand side of the abstract portal. Technical support for Administrative Application users is provided by email during the hours of 9:00 am to 5:00 pm CT on regular working days (excluding weekends and holidays).

Preparing an Abstract for Submission

Please read the formatting guidelines before submission. Abstracts that are incorrectly formatted may be returned prior to review.

Contact Information

• Your name, degree, institution, address, phone number, and email address must be provided. As the corresponding author, you will receive all future correspondence from ACMG.
• The submitting author should be the first author (presenter) of the abstract, unless otherwise noted during submission.

Co-Authors

• Names of co-authors and institutions must be provided. Changes will not be made to the spelling of authors’ names after the submission deadline; please proof your co-authors’ names carefully.

Copyright Policy

• All authors must assign copyright of the abstract to ACMG, unless one of the authors is a U.S. Federal employee (in such case, ACMG does not hold copyright).

Abstract Title

• The abstract title should be brief and clearly indicate the nature of the abstract. You may use up to 20 words.
• The abstract title must be in title case. Capitalize all nouns, pronouns, adjectives, verbs, adverbs, and subordinate conjunctions (i.e., as, because, although). Except for the first word of the title, lowercase all articles, coordinate conjunctions (i.e., and, or, nor), and prepositions, regardless of length. Also, lowercase “to” when used as an infinitive. See examples here.
• Additionally, keep letters lowercase if the lowercase letters have a specific meaning, such as aCGH or NIPS.
•  Do not put a period at the end of the title.
• For example: Cancer Genetics: Translation of New Concepts to Clinical Care

Use of Product Names

• Non-proprietary (generic/scientific) names should be used and should be lowercase.
• If necessary, you may include a proprietary name in parentheses directly following the generic name after its first mention in the body of the abstract; the first letter of the name of a proprietary drug should be capitalized. ACMG reserves the right to replace proprietary names with generic names to adhere to this policy.

Abbreviations

• Use standard abbreviations. Place abbreviations in parentheses immediately after the first mention of a term or phrase; the abbreviation can then be used throughout the abstract.

Terminology

ACMG has preferred terminology that must be followed. We also require that all sequence variants follow HGVS nomenclature and that variants are classified as per the ACMG/AMP Guidelines.

Abstract Structure

• Abstracts submitted for the ACMG Annual Meeting are published online. it is the responsibility of the author to proofread the abstract carefully.
• You are allotted 600 words for your abstract. The program will not allow submission if the maximum number is exceeded.
• The abstract must be structured (i.e., abstracts divided into sections using the terms Introduction, Methods, Results, Conclusions). Case reports should follow this structure: Background, Case presentation, Conclusions.
• Do not use bold type or underline formatting. Italic type is acceptable.
• Text may be in multiple paragraphs.
• Special Greek and mathematical symbols are available in a character map within the submission system.
• Use numerals to indicate numbers, except when beginning sentences.
• Figures, diagrams, and images of patients should not be included.
• No references are allowed.
• No tables are allowed.

David L. Rimoin Inspiring Excellence Award

The ACMG Foundation for Genetic and Genomic Medicine will award the David L. Rimoin Inspiring Excellence Award to a selected student, trainee, or junior faculty ACMG member whose abstract submission in the clinical genetics and therapeutics category is chosen as a platform presentation during the 2023 ACMG Annual Clinical Genetics Meeting. In recognition of their selected presentation, the Rimoin Fund will provide a cash award of $1,000 and cover the travel costs for the recipient to attend the meeting.

How to be considered for the David L. Rimoin Inspiring Excellence Award:

• All geneticists-in-training, who are both first author and presenter of the abstract in the clinical genetics and therapeutics category, are considered for an Abstract Award. Therefore, you must identify as a geneticist–in-training and then select the appropriate training category (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) in the online abstract submission system.
• As a geneticist-in-training, you are required to submit a letter from the senior investigator overseeing your research confirming your status as a geneticist-in-training. The deadline for receipt of the geneticist-in-training letter is, therefore, November 18, 2022. There will be no exceptions.
• Your letter must be typed on your institution’s letterhead, signed by the senior investigator, saved in PDF format, and uploaded to the online abstract submission system.
• Please include the following items in your letter: Author name (this is the geneticist-in-training who is the presenting/contact author); Confirmation of your status as a geneticist-in-training.
• Abstract Award recipients will be notified if they will receive an award the week of December 13, 2022. You must register and attend the meeting and present your abstract to receive your award.

Eligible candidates interested in entering the competition will indicate so during the abstract submission process.

Carolyn Mills Lovell Genetic Counselors Award

ACMG supports special recognition and a Carolyn Mills Lovell Genetic Counselors Award for a high-scoring abstract submitted by a genetic counselor.

The ACMG Foundation for Genetic and Genomic Medicine will be giving the Carolyn Mills Lovell Genetic Counselors Award to the first author of the highest-rated genetic counselor-authored abstract submission for the scientific program during the 2023 ACMG Annual Clinical Genetics Meeting.

How to be considered for the Carolyn Mills Lovell Genetic Counselors Award

• The Carolyn Mills Lovell Genetic Counselors Award will be presented to the recipient at the 2023 ACMG Annual Clinical Genetics Meeting. In recognition of their selected presentation, a $1,000 cash award will be given to the recipient.
• Applicants must be certified- or board-eligible Genetic Counselors or genetic counseling graduate students enrolled in an accredited genetic counseling training program and do not have to be ACMG members.
• Eligible candidates interested in entering the competition will indicate so during the abstract submission process.

Completion of all required information in the online abstract submission system serves as an agreement. It certifies the ACMG abstract submitter's understanding of the rules for participation contained in the online abstract submission program and affirms that:

1. All authors approve of submitting this work for presentation and publication;
2. The author(s) transfer(s) all copyright ownership of the named abstract to the American College of Medical Genetics and Genomics (except when one or more authors are U.S. Government employees);
3. Submitter is acting on behalf of authors and has read the ACMG Conflict-of-Interest Policy and has acted in accordance with that policy;
4. The author(s) agree(s) to materially confine the presentation to information in the abstract, if accepted for presentation. If an author has more than one abstract accepted, each presentation will be materially confined to the information in the abstract selected for the specific session;
5. The presenting author will be available to present the abstract if selected for the program. The author(s) will immediately notify ACMG if the first author is not the presenting author. Presenting author will be required to complete presenter documents including financial disclosure.

Contact Information
Send related correspondence and questions regarding abstract submissions or notifications to education@acmg.net.

Please note that submitting an abstract does not register you for the ACMG Annual Meeting. View rates, deadlines and register here.